Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity

Chemico-Biological Interactions

Volumn 179, Issue 1, 2009, Pages 60-67

  Smith, Dennis A ^a   Obach, R Scott ^b   Williams, Dominic P ^a   Park, B Kevin ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b University of Liverpool ^*

Author keywords

Concentration response; Dose response; Dosing duration; Human carcinogens; Latency; Off target pharmacology; On target pharmacology

Indexed keywords

ANTICONVULSIVE AGENT; BENAZEPRIL; BROMFENAC; CAPTOPRIL; CARBAMAZEPINE; CARCINOGEN; CLOZAPINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOLASETRON MESILATE; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ENALAPRIL; FELABAMATE; FELBAMATE; FENFLURAMINE; FOSINOPRIL; LISINOPRIL; NIMESULIDE; NORFENFLURAMINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; RISPERIDONE; TOLCAPONE; TRAMADOL; TROGLITAZONE; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

AGRANULOCYTOSIS; ANGIONEUROTIC EDEMA; APLASTIC ANEMIA; ARTICLE; ATAXIA; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; FIBROMA; FIBROMYXOID PLAQUE; HUMAN; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; MYDRIASIS; PARESTHESIA; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREMOR; VALVULAR HEART DISEASE;

CARCINOGENS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; TOXICITY TESTS;

EID: 59649084532     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.09.022     Document Type: Article

References (38)

1. Smith D.A., and Obach R.S. Seeing through the MIST. Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33 10 (2005) 1409-1417
2. Smith D.A., and Obach R.S. Metabolites and safety: what are the concerns, and how should we address them?. Chem. Res. Toxicol. 19 12 (2006) 1570-1579
3. Aronson J.K. The International Encyclopedia of Adverse Drug Reactions and Interactions. 15th ed. (2006), Elsevier (Chapter 7, pp. 560-610)
4. Gleason P.P., Frye R.F., and O'toole T. Debilitating reaction following the initial dose of tramadol. Ann. Pharmacother. 31 10 (1997) 1150-1152
5. Sondhi D., Lippman M., and Murah G. Airways compromise due to angiotensin-converting enzyme inhibitor-induced angioedema. Chest 126 2 (2004) 400-404
6. Documented in the Product Label available from the FDA website. http://www.fda.gov/cder/foi/label/2007/020623s006,020624s016lbl.pdf.
7. Smith D.A., and Schmid E.F. Drug Withdrawals and the lessons within. Curr. Opin. Drug Disc. Dev. 9 1 (2006) 38-46
8. Jick H., Vasilakis C., Weinrauch L.A., Meier C., Jick S.S., and Derby L.E. A population based study of appetite suppressant drugs and the risk of cardiac valve regurgitation. New Engl. J. Med. 339 11 (1998) 719-724
9. Li R., Serdula M.K., Williamson D.F., Bowman B.A., Graham D.J., and Green L. Dose-effect of fenfluramine use on severity of valvular heart disease among fen-phen patients with valvulopathy. Int. J. Obesity 23 9 (1999) 926-928
10. Pellock J.M. Felbamate in epilepsy therapy, evaluating the risks. Drug Safety 21 3 (1999) 225-239
11. Goldkind L., and Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicty: lessons learned from the bromfenac experience. Pharmacoepidemiol. Drug Safety 15 4 (2000) 213-220
12. Graham D.J., Drinkard C.R., and Statin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am. J. Gastroenterol. 98 1 (2003) 175-179
13. Watkins P.B., Dube L.M., Walter-Bowen K., Cameron C.M., and Kasten L.E. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Safety 30 9 (2007) 805-815
14. Olanow C.W., and Watkins P.B. Tolcapone: an efficacy and safety review. Clin. Neuropharm. 30 5 (2007) 287-298
15. Ball P., Mandell L., Niki Y., and Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 21 5 (1999) 407-421
16. Phillips E.J., Liu B.A., and Knowles S.R. Rapid onset of risperidone-induced hepatotoxicity. Ann. Pharmacother. 32 7-8 (1998) 843
17. Kang B.-J., Cho M.-J., Oh J.-T., Lee Y., Chae B.-J., and Ko J. Long term monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?. Hum. Psychopharm. Clin. Exp. 21 6 (2006) 387-391
18. Mockenhaupt M., Viboud C., Dunant A., Naldi L., Halevy S., Bavinck J.N.B., Sidoroff A., Scneck J., Roujeau J.-C., and Flahault A. Stevens-Johnson syndrome and toxic epidermal necrosis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J. Invest. Dermatol. 128 1 (2008) 35-44
19. Boelsterli U.A. Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors. Int. J. Clin. Pract. 128 Suppl. (2002) 30-36
20. de Jonge M.E., Huitema A.D.R., Rodenhuis S., and Beijnen H. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 44 11 (2005) 1135-1164
21. Fleming R.A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17 5 pt 2 (1997) 146S-154S
22. Peto R., Gray P., Brantom P., and Grasso P. Dose and time relationships for tumour induction in the liver and oesophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine. Cancer Res. 51 23 pt 2 (1991) 6452-6468
23. Doll R., and Peto R. Cigarette smoking and bronchial carcinoma: dose and time relationship amongst regular and lifelong non-smokers. J. Epidemiol. Community Health 32 4 (1978) 303-313
24. Peto R. Influence of dose and duration on lung cancer rates. IARC Sci. Publ. 74 (1986) 23-33
25. Knoke J.D., Shanks T.G., Vaughan J.W., Thun M.J., and Burns D.M. Lung cancer mortality is related to age in addition to duration and intensity of cigarette smoking: an analysis of CPS-I data. Cancer Epidemiol. Biomark. 13 6 (2004) 949-957
26. Flanders W.D., Lally C.A., Zhu B.P., Henley S.J., and Thun M.J. Lung cancer mortality in relation to age, duration of smoking and daily cigarette consumption: results from the cancer prevention study II. Cancer Res. 63 19 (2003) 6556-6562
27. Montesano R., Hain P., and Wild C.P. Hepatocellular carcinoma: from gene to public health. J. Natl. Cancer Inst. 89 24 (1997) 1844-1851
28. Kirk G.D., Bah E., and Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from the Gambia, West Africa. Carcinogenesis 27 10 (2006) 2070-2082
29. Hemstreet G.P., Schuklte P.A., Ringen K., Stringer W., and Altekruse E.B. DNA hyperploidy as a marker for biological response to bladder carcinogen exposure. Int. J. Cancer 42 6 (1988) 817-820
30. Guenel P., Imbernon E., Chevalier A., Crinquand-Calastreng A., and Goldberg M. Leukemia in relation to occupational exposures to benzene and other agents: a case-control study nested in a cohort of gas and electric utility workers. Am. J. Ind. Med. 42 2 (2002) 87-97
31. Steenland K., Piacitelli L., Deddens J., Fingerhut M., and Chang I. Cancer, heart disease and diabetes in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Natl. Cancer Inst. 91 9 (1999) 779-786
32. Nurminen M., Karjalainen A., and Takahashi K. Estimating the induction period of pleural mesothelioma from aggregate data on asbestos consumption. JOEM 45 10 (2003) 1107-1115
33. Infante F. Benzene exposure and multiple myeloma, a detailed meta analysis of benzene cohort studies. Ann. NY Acad. Sci. 1076 (2006) 90-109 (living in a chemical world)
34. Radis C.D., Kahl L.E., Baker G.L., Wasko M.C.M., Cash J.M., Gallatin A., Stolzer B.L., Agarwal A.K., Medsger T.A., and Kwoh C.K. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow up study. Arthritis Rheum. 38 8 (1995) 1120-1127
35. Jones R.D., Smith D.M., and Thomas P.G. A mortality study of vinyl chloride monomer workers employed in the United Kingdom in 1940-1974, Scand. J. Work. Environ. Health 14 3 (1988) 153-160
36. Hallas J., and Stovring H. Templates for analysis of individual-level prescription data. Basic Clin. Pharm. Toxicol. 98 3 (2006) 260-265
37. Lagnaoui R., Depout F., Fourrier A., Abouelfath A., Begaud B., Verdoux H., and Moore N. Patterns and correlates of benzodiazepine use in the French general population. Eur. J. Clin. Pharmacol. 60 7 (2004) 523-529
38. Monro A., and Davies T.S. High dose levels are not necessary in rodent studies to detect human carcinogens. Cancer Lett. 75 3 (1993) 183-194